Towards a new classification of systemic sclerosis

Monique Hinchcliff¹, J Matthew Mahoney^{2

3}

Affiliations

¹ Yale School of Medicine, Section of Allergy, Rheumatology and Immunology, New Haven, CT, USA. monique.hinchcliff@yale.edu.
² Department of Neurological Sciences, University of Vermont Larner College of Medicine, Burlington, VT, USA.
³ Department of Computer Science, University of Vermont, Burlington, VT, USA.

Comment

Monique Hinchcliff et al. Nat Rev Rheumatol. 2019 Aug.

. 2019 Aug;15(8):456-457.

doi: 10.1038/s41584-019-0257-z.

Monique Hinchcliff¹, J Matthew Mahoney^{2

3}

¹ Yale School of Medicine, Section of Allergy, Rheumatology and Immunology, New Haven, CT, USA. monique.hinchcliff@yale.edu.
² Department of Neurological Sciences, University of Vermont Larner College of Medicine, Burlington, VT, USA.
³ Department of Computer Science, University of Vermont, Burlington, VT, USA.

No abstract available

Comment on

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.
Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E; EUSTAR Collaborators. Sobanski V, et al. Arthritis Rheumatol. 2019 Sep;71(9):1553-1570. doi: 10.1002/art.40906. Epub 2019 Aug 12. Arthritis Rheumatol. 2019. PMID: 30969034 Free PMC article.